Connecta Therapeutics raises €1.7 M to develop new treatment for fragile X syndrome

by Parc Científic de Barcelona

Connecta Therapeutics has closed a €1.7 million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have frag...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream